Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Here's Why

Key Points

• Shares of Zealand Pharma A/S gapped up from $61.00 to $66.00 prior to trading on Monday, with a notable trading volume of 110 shares.
• Analysts have mixed ratings for the stock, with five recognizing it as a Strong Buy and one as a Sell, leading to a consensus rating of Buy.
• In its latest earnings report, the company missed EPS estimates, posting $16.06 while expected was $16.72, with reported revenue significantly below analyst expectations.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $61.00, but opened at $66.00. Zealand Pharma A/S shares last traded at $66.00, with a volume of 110 shares.

Analysts Set New Price Targets

Several analysts recently commented on ZLDPF shares. Zacks Research lowered Zealand Pharma A/S from a "hold" rating to a "strong sell" rating in a report on Friday, August 15th. Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Finally, Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Five equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S presently has an average rating of "Buy".

Zealand Pharma A/S Stock Performance

The stock has a market cap of $4.89 billion, a P/E ratio of 4.83 and a beta of 0.71. The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average price of $57.53 and a two-hundred day moving average price of $68.62.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $9.18 billion. Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%. On average, sell-side analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.